8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Collegium Pharmaceutical, Inc.(COLL)Earnings, Financials & Key Ratios
COLL•NASDAQ
19.4× P/E·Price updated Jun 19, 2026
AboutCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Show more
- Revenue$781M+23.6%
- EBITDA$413M+21.9%
- Net Income$63M-9.1%
- EPS (Diluted)1.73-7.0%
- Gross Margin59.35%-0.7%
- EBITDA Margin52.93%-1.4%
- Operating Margin23.97%-10.9%
- Net Margin8.05%-26.5%
- ROE23.7%-27.3%
COLL Key Insights
Collegium Pharmaceutical, Inc. (COLL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 27.0%
- ✓Strong 5Y profit CAGR of 18.6%
- ✓FCF machine: 42.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 20.3%
✗Weaknesses
- ✗High debt to equity ratio of 3.1x
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when COLL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COLL Price & Volume
Collegium Pharmaceutical, Inc. (COLL) stock price & volume — 10-year historical chart
Loading chart...
COLL Growth Metrics
Collegium Pharmaceutical, Inc. (COLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years20.28%
3 Years18.94%
TTM19.88%
Profit CAGR
10 Years-
5 Years18.64%
3 Years-
TTM70.75%
EPS CAGR
10 Years-
5 Years17.88%
3 Years-
TTM68.09%
Return on Capital
10 Years-9.63%
5 Years13.55%
3 Years19.22%
Last Year15.78%
COLL Recent Earnings
Collegium Pharmaceutical, Inc. (COLL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.76+15.8%
$1.52
Rev
$194M+4.9%
$184M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$2.04-4.7%
$2.14
Rev
$205M-0.4%
$206M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$2.25+21.0%
$1.86
Rev
$209M+1.6%
$206M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.68+3.7%
$1.62
Rev
$188M-1.7%
$191M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.76vs $1.52+15.8% | $194Mvs $184M+4.9% |
| Q1 2026 | Feb 26, 2026 | $2.04vs $2.14-4.7% | $205Mvs $206M-0.4% |
| Q4 2025 | Nov 6, 2025 | $2.25vs $1.86+21.0% | $209Mvs $206M+1.6% |
| Q3 2025 | Aug 7, 2025 | $1.68vs $1.62+3.7% | $188Mvs $191M-1.7% |
Based on last 12 quarters of dataView full earnings history →
COLL Peer Comparison
Collegium Pharmaceutical, Inc. (COLL) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 HRMY | 1.93B | 33.28 | 12.28 | 21.51% | 16.2% | 17.19% | 0.28 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% | |||
 CAH | 52.19B | 221.77 | 34.38 | -1.87% | 0.62% | |||
 CVS | 125.45B | 98.32 | 70.73 | 7.85% | 0.72% | 3.86% | 1.24 |
Compare COLL vs Peers
Collegium Pharmaceutical, Inc. (COLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COLL Income Statement
Collegium Pharmaceutical, Inc. (COLL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 28.48M | 280.41M | 296.7M | 310.02M | 276.87M | 463.93M | 566.77M | 631.45M | 780.57M | 796.33M |
Revenue Growth % | 1564.29% | 884.73% | 5.81% | 4.49% | -10.69% | 67.56% | 22.17% | 11.41% | 23.62% | 19.88% |
Cost of Goods Sold | 2.6M | 165.68M | 193.66M | 130.18M | 126.25M | 254.44M | 240.6M | 254.1M | 317.31M | 313.15M |
COGS % of Revenue | 9.11% | 59.08% | 65.27% | 41.99% | 45.6% | 54.85% | 42.45% | 40.24% | 40.65% | - |
Gross Profit | 25.88M▲ 0% | 114.74M▲ 343.3% | 103.04M▼ 10.2% | 179.84M▲ 74.5% | 150.62M▼ 16.2% | 209.49M▲ 39.1% | 326.17M▲ 55.7% | 377.34M▲ 15.7% | 463.26M▲ 22.8% | 483.18M▲ 0% |
Gross Margin % | 90.89% | 40.92% | 34.73% | 58.01% | 54.4% | 45.15% | 57.55% | 59.76% | 59.35% | 60.68% |
Gross Profit Growth % | 1627.7% | 343.32% | -10.19% | 74.53% | -16.25% | 39.09% | 55.7% | 15.69% | 22.77% | - |
Operating Expenses | 101.33M | 135.42M | 126.79M | 123.6M | 132.99M | 176.17M | 159.21M | 207.45M | 276.17M | 293.26M |
OpEx % of Revenue | 355.84% | 48.29% | 42.73% | 39.87% | 48.03% | 37.97% | 28.09% | 32.85% | 35.38% | - |
Selling, General & Admin | 92.76M | 126.76M | 116.45M | 113.83M | 118.96M | 172.19M | 159.21M | 182.98M | 276.17M | 206.83M |
SG&A % of Revenue | 325.73% | 45.2% | 39.25% | 36.72% | 42.97% | 37.11% | 28.09% | 28.98% | 35.38% | - |
Research & Development | 8.57M | 8.66M | 10.34M | 9.77M | 9.45M | 3.98M | 0 | 0 | 0 | 0 |
R&D % of Revenue | 30.1% | 3.09% | 3.48% | 3.15% | 3.41% | 0.86% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 4.58M | 0 | 0 | 24.47M | 0 | 1.64M |
Operating Income | -75.45M▲ 0% | -20.68M▲ 72.6% | -23.75M▼ 14.8% | 56.23M▲ 336.8% | 17.63M▼ 68.7% | 33.32M▲ 89.0% | 166.96M▲ 401.1% | 169.9M▲ 1.8% | 187.08M▲ 10.1% | 189.91M▲ 0% |
Operating Margin % | -264.95% | -7.38% | -8% | 18.14% | 6.37% | 7.18% | 29.46% | 26.91% | 23.97% | 23.85% |
Operating Income Growth % | 19.81% | 72.58% | -14.81% | 336.79% | -68.65% | 89.01% | 401.1% | 1.76% | 10.12% | - |
EBITDA | -74.85M | 90.22M | -8.27M | 117.78M | 86.55M | 172.26M | 316.22M | 339.06M | 413.16M | 528.7M |
EBITDA Margin % | -262.86% | 32.17% | -2.79% | 37.99% | 31.26% | 37.13% | 55.79% | 53.69% | 52.93% | 66.39% |
EBITDA Growth % | 19.88% | 220.53% | -109.16% | 1525.07% | -26.52% | 99.04% | 83.57% | 7.22% | 21.86% | 59.06% |
D&A (Non-Cash Add-back) | 594K | 110.91M | 15.48M | 61.55M | 68.92M | 138.94M | 149.26M | 169.16M | 226.07M | 338.79M |
EBIT | -74.86M | -19M | -21.81M | 56.46M | 17.64M | 34.37M | 159.07M | 172.54M | 174.93M | 268.49M |
Net Interest Income | 582K | -18.44M | 1.03M | -28.65M | -21M | -62.17M | -67.72M | -60M | -71.02M | -150.12M |
Interest Income | 582K | 1.69M | 1.94M | 232K | 12K | 1.05M | 15.62M | 13.98M | 11.29M | 12.77M |
Interest Expense | 0 | 20.13M | 909K | 28.88M | 21.01M | 63.21M | 83.34M | 73.97M | 82.31M | 162.89M |
Other Income/Expense | 582K | -18.44M | 1.03M | -28.65M | -21M | -62.17M | -91.23M | -71.33M | -94.47M | -81.68M |
Pretax Income | -74.86M▲ 0% | -39.13M▲ 47.7% | -22.72M▲ 41.9% | 27.58M▲ 221.4% | -3.37M▼ 112.2% | -28.85M▼ 755.0% | 75.73M▲ 362.5% | 98.57M▲ 30.2% | 92.62M▼ 6.0% | 108.24M▲ 0% |
Pretax Margin % | -262.91% | -13.95% | -7.66% | 8.9% | -1.22% | -6.22% | 13.36% | 15.61% | 11.87% | 13.59% |
Income Tax | 0 | 0 | 0 | 830K | -74.89M | -3.85M | 27.58M | 29.38M | 29.75M | 33.29M |
Effective Tax Rate % | 0% | 0% | 0% | 3.01% | 2219.65% | 13.33% | 36.41% | 29.8% | 32.12% | 30.75% |
Net Income | -74.86M▲ 0% | -39.13M▲ 47.7% | -22.72M▲ 41.9% | 26.75M▲ 217.7% | 71.52M▲ 167.3% | -25M▼ 135.0% | 48.16M▲ 292.6% | 69.19M▲ 43.7% | 62.87M▼ 9.1% | 74.95M▲ 0% |
Net Margin % | -262.91% | -13.95% | -7.66% | 8.63% | 25.83% | -5.39% | 8.5% | 10.96% | 8.05% | 9.41% |
Net Income Growth % | 20.51% | 47.74% | 41.93% | 217.74% | 167.33% | -134.96% | 292.6% | 43.68% | -9.13% | 70.75% |
Net Income (Continuing) | -74.86M | -39.13M | -22.72M | 26.75M | 71.52M | -25M | 48.16M | 69.19M | 62.87M | 74.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.47▲ 0% | -1.19▲ 51.8% | -0.24▲ 79.8% | 0.76▲ 416.7% | 1.86▲ 144.7% | -0.74▼ 139.8% | 1.29▲ 274.3% | 1.86▲ 44.2% | 1.73▼ 7.0% | 1.87▲ 0% |
EPS Growth % | 36.34% | 51.82% | 79.83% | 416.67% | 144.74% | -139.78% | 274.32% | 44.19% | -6.99% | 68.09% |
EPS (Basic) | -2.47 | -1.19 | -0.24 | 0.78 | 2.05 | -0.74 | 1.60 | 2.14 | 1.98 | - |
Diluted Shares Outstanding | 30.27M | 32.95M | 33.45M | 35.15M | 41.05M | 33.83M | 41.79M | 40.42M | 39.7M | 40.07M |
Basic Shares Outstanding | 30.27M | 32.88M | 33.45M | 34.41M | 34.94M | 33.83M | 33.74M | 32.27M | 31.71M | 32.09M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
COLL Balance Sheet
Collegium Pharmaceutical, Inc. (COLL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 133.48M | 237.51M | 255.72M | 277.89M | 315.54M | 419.99M | 537.6M | 482.26M | 691.41M | 745.67M |
Cash & Short-Term Investments | 118.7M | 146.63M | 170.02M | 174.12M | 186.43M | 173.69M | 310.55M | 162.76M | 406.53M | 421.75M |
Cash Only | 118.7M | 146.63M | 170.02M | 174.12M | 186.43M | 173.69M | 238.95M | 70.56M | 251.1M | 268.65M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 71.6M | 92.2M | 155.43M | 153.1M |
Accounts Receivable | 9.97M | 77.95M | 72.95M | 83.32M | 105.84M | 183.12M | 179.53M | 228.54M | 211.33M | 228.76M |
Days Sales Outstanding | 127.78 | 101.46 | 89.75 | 98.1 | 139.54 | 144.07 | 115.61 | 132.1 | 98.82 | 101.65 |
Inventory | 1.81M | 7.82M | 9.64M | 15.61M | 17.39M | 46.5M | 32.33M | 35.56M | 40.91M | 42.74M |
Days Inventory Outstanding | 255.01 | 17.22 | 18.17 | 43.78 | 50.29 | 66.71 | 49.05 | 51.08 | 47.06 | 46.58 |
Other Current Assets | 456K | 1.01M | 141K | 60K | 27K | 57K | 93K | 27.74M | 3.24M | 52.41M |
Total Non-Current Assets | 2.08M | 53.73M | 50.58M | 365.95M | 376.53M | 754.14M | 605.71M | 1.18B | 965.42M | 906.29M |
Property, Plant & Equipment | 1.83M | 9.27M | 20.9M | 27.38M | 27.14M | 26.38M | 22.01M | 20.15M | 16.2M | 15.64M |
Fixed Asset Turnover | 15.59x | 30.24x | 14.20x | 11.32x | 10.20x | 17.59x | 25.75x | 31.34x | 48.18x | 47.77x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 133.69M | 133.86M | 162.33M | 145.93M | 145.93M |
Intangible Assets | 0 | 44.26M | 29.5M | 335.9M | 268.72M | 567.47M | 421.71M | 891.4M | 669.51M | 614.04M |
Long-Term Investments | 97K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M | 2.11M |
Other Non-Current Assets | 161K | 204K | 178K | 2.67M | 2.63M | 2.65M | 1.87M | 9.41M | 20.19M | 17.12M |
Total Assets | 135.57M▲ 0% | 291.25M▲ 114.8% | 306.3M▲ 5.2% | 643.84M▲ 110.2% | 692.08M▲ 7.5% | 1.17B▲ 69.7% | 1.14B▼ 2.6% | 1.66B▲ 45.5% | 1.66B▼ 0.4% | 1.65B▲ 0% |
Asset Turnover | 0.21x | 0.96x | 0.97x | 0.48x | 0.40x | 0.40x | 0.50x | 0.38x | 0.47x | 0.49x |
Asset Growth % | -16.32% | 114.83% | 5.17% | 110.2% | 7.49% | 69.65% | -2.63% | 45.51% | -0.41% | 50.34% |
Total Current Liabilities | 31.49M | 187.48M | 201.76M | 239.45M | 279.57M | 433.73M | 457.92M | 509.51M | 440.03M | 434.97M |
Accounts Payable | 5.68M | 12.15M | 6.25M | 10.02M | 4.19M | 3.49M | 8.69M | 3.93M | 10.66M | 6.83M |
Days Payables Outstanding | 799.48 | 26.77 | 11.77 | 28.08 | 12.11 | 5.01 | 13.19 | 5.65 | 12.26 | 10.5 |
Short-Term Debt | 1.48M | 1.64M | 3.83M | 47.49M | 48.35M | 162.5M | 183.33M | 64.58M | 30.41M | 34.07M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 988K | 0 | 667K | 2M |
Other Current Liabilities | 18.21M | 167.7M | 5.7M | 1.42M | 851K | 1.51M | 253.91M | 7.61M | 378.73M | 393.4M |
Current Ratio | 4.24x | 1.27x | 1.27x | 1.16x | 1.13x | 0.97x | 1.17x | 0.95x | 1.57x | 1.71x |
Quick Ratio | 4.18x | 1.23x | 1.22x | 1.10x | 1.07x | 0.86x | 1.10x | 0.88x | 1.48x | 1.62x |
Cash Conversion Cycle | -416.7 | 91.91 | 96.15 | 113.79 | 177.71 | 205.76 | 151.48 | 177.53 | 133.62 | 137.73 |
Total Non-Current Liabilities | 7.16M | 12.18M | 17.11M | 218.36M | 209.58M | 545.56M | 489.96M | 925.24M | 915.13M | 904.56M |
Long-Term Debt | 0 | 9.86M | 7.67M | 209.59M | 201.63M | 538.45M | 483.84M | 787.9M | 906.02M | 773.98M |
Capital Lease Obligations | 0 | 0 | 9.44M | 8.77M | 7.95M | 7.11M | 6.12M | 5.54M | 4.13M | 17.27M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 676K | 0 | 0 | 0 | 0 | 0 | 121.8M | -4.13M | 130.58M |
Total Liabilities | 31.49M | 199.66M | 218.87M | 457.81M | 489.15M | 979.29M | 947.88M | 1.43B | 1.36B | 1.34B |
Total Debt | 1.48M | 11.5M | 21.59M | 266.58M | 258.75M | 709.17M | 674.28M | 859.3M | 940.56M | 808.06M |
Net Debt | -117.22M | -135.13M | -148.43M | 92.47M | 72.32M | 535.49M | 435.34M | 788.73M | 689.46M | 539.41M |
Debt / Equity | 0.01x | 0.13x | 0.25x | 1.43x | 1.28x | 3.64x | 3.45x | 3.75x | 3.12x | 2.59x |
Debt / EBITDA | - | 0.13x | - | 2.26x | 2.99x | 4.12x | 2.13x | 2.53x | 2.28x | 1.53x |
Net Debt / EBITDA | - | -1.50x | - | 0.79x | 0.84x | 3.11x | 1.38x | 2.33x | 1.67x | 1.02x |
Interest Coverage | - | -0.94x | -24.00x | 1.95x | 0.84x | 0.54x | 1.91x | 2.33x | 2.13x | 1.65x |
Total Equity | 104.08M▲ 0% | 91.58M▼ 12.0% | 87.43M▼ 4.5% | 186.03M▲ 112.8% | 202.93M▲ 9.1% | 194.84M▼ 4.0% | 195.43M▲ 0.3% | 228.84M▲ 17.1% | 301.68M▲ 31.8% | 312.42M▲ 0% |
Equity Growth % | -22.85% | -12.01% | -4.53% | 112.77% | 9.08% | -3.98% | 0.3% | 17.1% | 31.83% | 89.61% |
Book Value per Share | 3.44 | 2.78 | 2.61 | 5.29 | 4.94 | 5.76 | 4.68 | 5.66 | 7.60 | 7.80 |
Total Shareholders' Equity | 104.08M | 91.58M | 87.43M | 186.03M | 202.93M | 194.84M | 195.43M | 228.84M | 301.68M | 312.42M |
Common Stock | 33K | 33K | 34K | 35K | 36K | 37K | 38K | 40K | 41K | 41K |
Retained Earnings | -298.05M | -337.18M | -359.9M | -333.15M | -256.34M | -281.34M | -233.19M | -164M | -101.13M | -86.63M |
Treasury Stock | 0 | 0 | 0 | 0 | -42.86M | -61.92M | -137.38M | -197.5M | -222.51M | -222.51M |
Accumulated OCI | -1.67M | 0 | 0 | 0 | 0 | 0 | 14K | 55K | 319K | -219K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COLL Cash Flow Statement
Collegium Pharmaceutical, Inc. (COLL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -67.02M | 169.39M | 27.78M | 93.94M | 103.56M | 124.23M | 274.75M | 204.98M | 329.32M | 331.04M |
Operating CF Margin % | -235.35% | 60.41% | 9.36% | 30.3% | 37.4% | 26.78% | 48.48% | 32.46% | 42.19% | - |
Operating CF Growth % | 10.71% | 352.75% | -83.6% | 238.13% | 10.23% | 19.96% | 121.16% | -25.39% | 60.66% | 1027.58% |
Net Income | -74.86M | -39.13M | -22.72M | 26.75M | 71.52M | -25M | 48.16M | 69.19M | 62.87M | 74.95M |
Depreciation & Amortization | 594K | 110.91M | 15.48M | 61.55M | 68.92M | 138.94M | 149.26M | 169.16M | 220.82M | 227.86M |
Stock-Based Compensation | 7.95M | 13.78M | 16.53M | 21.91M | 24.25M | 22.87M | 27.14M | 32.4M | 41.91M | 41.26M |
Deferred Taxes | 1.84M | 0 | 0 | 0 | -78.04M | -8.39M | -2.15M | -26.81M | -25.66M | -26.09M |
Other Non-Cash Items | -34K | 19.28M | -5.59M | 9.03M | 3.42M | 8.52M | 30.62M | 16.02M | 25.62M | 17.44M |
Working Capital Changes | -2.5M | 64.55M | 24.08M | -25.3M | 13.49M | -12.71M | 21.73M | -54.98M | 3.76M | -4.39M |
Change in Receivables | -7.84M | -68.23M | 4.99M | -10.37M | -22.52M | -21.78M | 3.59M | -4.41M | 17.2M | -60K |
Change in Inventory | -497K | 219K | -1.83M | -8.27M | -2.3M | 48.27M | 14.17M | 13.93M | -5.35M | -5.52M |
Change in Payables | -3.42M | 6.46M | 0 | 3.77M | -5.83M | -707K | 5.06M | -11.28M | 6.72M | -11.03M |
Cash from Investing | -990K | -24.35M | -6.44M | -373.77M | -1.94M | -573.69M | -70.81M | -287.76M | -63.53M | -52.23M |
Capital Expenditures | -990K | -24.35M | -6.44M | -5.55M | -1.94M | -1.62M | -461K | -1.65M | -1.74M | -1.21M |
CapEx % of Revenue | 3.48% | 8.69% | 2.17% | 1.79% | 0.7% | 0.35% | 0.08% | 0.26% | 0.22% | 0.15% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -572.07M | 0 | -267.54M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -18.88M | 0 | -368.23M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 33.48M | -117.2M | 2.04M | 286.47M | -89.3M | 436.72M | -140.18M | -60.6M | -110.25M | -106.35M |
Debt Issued (Net) | -2.67M | 10.02M | 0 | 281.39M | -50M | 442.68M | -65.92M | 7.52M | -70.38M | -61.49M |
Equity Issued (Net) | 34.34M | -30K | -822K | 0 | -47.86M | -14.06M | -75M | -60.02M | -19.46M | -20.18M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -560K | -822K | 0 | -47.86M | -14.06M | -75M | -60.02M | -25.1M | -25.1M |
Other Financing | 1.81M | -127.19M | 2.86M | 5.08M | 8.56M | 8.1M | 740K | -8.1M | -20.4M | -24.69M |
Net Change in Cash | -34.53M▲ 0% | 27.84M▲ 180.6% | 23.39M▼ 16.0% | 6.64M▼ 71.6% | 12.31M▲ 85.3% | -12.74M▼ 203.5% | 63.76M▲ 600.5% | -143.38M▼ 324.9% | 155.55M▲ 208.5% | 172.46M▲ 0% |
Free Cash Flow | -68.01M▲ 0% | 145.04M▲ 313.3% | 21.34M▼ 85.3% | -279.83M▼ 1411.0% | 101.61M▲ 136.3% | 122.61M▲ 20.7% | 274.29M▲ 123.7% | 203.33M▼ 25.9% | 327.58M▲ 61.1% | 329.83M▲ 0% |
FCF Margin % | -238.83% | 51.72% | 7.19% | -90.26% | 36.7% | 26.43% | 48.4% | 32.2% | 41.97% | 41.42% |
FCF Growth % | 12.84% | 313.26% | -85.28% | -1410.99% | 136.31% | 20.66% | 123.71% | -25.87% | 61.11% | 67.8% |
FCF per Share | -2.25 | 4.40 | 0.64 | -7.96 | 2.48 | 3.62 | 6.56 | 5.03 | 8.25 | 8.23 |
FCF Conversion (FCF/Net Income) | 0.90x | -4.33x | -1.22x | 3.51x | 1.45x | -4.97x | 5.71x | 2.96x | 5.24x | 4.40x |
Interest Paid | 0 | 0 | 709K | 18.97M | 17.61M | 52.53M | 73.26M | 62.43M | 0 | 13.85M |
Taxes Paid | 0 | 0 | 0 | 483K | 3M | 10.4M | 24.2M | 52.09M | 0 | 29.82M |
COLL Key Ratios
Collegium Pharmaceutical, Inc. (COLL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -62.65% | -39.99% | -25.39% | 19.57% | 36.77% | -12.57% | 24.68% | 32.62% | 23.7% | 26.74% |
Return on Invested Capital (ROIC) | - | - | - | 38.78% | 4.78% | 4.97% | 18.4% | 15.46% | 13.97% | 14.88% |
Gross Margin | 90.89% | 40.92% | 34.73% | 58.01% | 54.4% | 45.15% | 57.55% | 59.76% | 59.35% | 60.68% |
Net Margin | -262.91% | -13.95% | -7.66% | 8.63% | 25.83% | -5.39% | 8.5% | 10.96% | 8.05% | 9.41% |
Debt / Equity | 0.01x | 0.13x | 0.25x | 1.43x | 1.28x | 3.64x | 3.45x | 3.75x | 3.12x | 2.59x |
Interest Coverage | - | -0.94x | -24.00x | 1.95x | 0.84x | 0.54x | 1.91x | 2.33x | 2.13x | 1.65x |
FCF Conversion | 0.90x | -4.33x | -1.22x | 3.51x | 1.45x | -4.97x | 5.71x | 2.96x | 5.24x | 4.40x |
Revenue Growth | 1564.29% | 884.73% | 5.81% | 4.49% | -10.69% | 67.56% | 22.17% | 11.41% | 23.62% | 19.88% |
Related:COLL Dividend History·COLL Revenue History·COLL Price History·COLL P/E History·COLL Financial Ratios·COLL Institutional Holders
COLL SEC Filings & Documents
Collegium Pharmaceutical, Inc. (COLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
COLL Frequently Asked Questions
Collegium Pharmaceutical, Inc. (COLL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Collegium Pharmaceutical, Inc. (COLL) reported $796.3M in revenue for fiscal year 2025.
Collegium Pharmaceutical, Inc. (COLL) grew revenue by 23.6% over the past year. This is strong growth.
Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $74.9M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 23.7%. This is excellent, indicating efficient use of shareholder capital.
Collegium Pharmaceutical, Inc. (COLL) generated $329.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.